In 2021, Nassiri et al. combined findings obtained with DNA somatic copy number aberrations, DNA somatic point mutations, DNA methylation, and messenger RNA abundance in 201 meningiomas of different WHO grades to identify four consensus molecular groups showing distinctive genetic alterations and proteomes [39], and named them immunogenic (MG1), benign NF2-wildtype (MG2), hypermetabolic (MG3), and proliferative (MG4) [39]. The gene discussed is NF2; the disease is meningioma.